ArticleJournal of thoracic disease2020

Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer.

Takeshi Masuda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.